Allena Pharmaceuticals Inc (ALNA) This company develops oral enzymes for difficult-to-treat metabolic diseases with their first-in-class oral biologic platform. They strive to help patients overcome the limitations of their disease.
This penny stock has seen highs of $16 in the past. They are leveraging their expertise in oral enzymes to develop first-of-its-kind therapies for the gastrointestinal (GI) tract that limit the effects of metabolic diseases, including kidney stones, gout, and chronic kidney disease. They also have several products in phases 2 and 3 of their pipeline.
Visit www.allenapharma.com to learn more.